1. INTERPRETAÇÃO DE
TRIALS RECENTES
VANISH - VT
Trail
Resultado
s
Diagnósti
co
Questões
Considerar
Lembra
r
Dr. Henrique Maia
Coordenador da Residência de
Eletrofisiologia IHBDF
Co-Fundador do ArritmoCardi
6. ECG
Grupos
Resultado
s
Questões
Considerar
Lembra
r
Análise de subgrupos
Mexiletine e Sotalol
Sucesso a longo
prazo
Efeitos Colaterais
Drazen JM et all . Statistics in medicine--reporting of subgroup
analyses in clinical trials. N Engl J Med. 2007;357(21):2189-94.
Não tiveram impacto nos resultados e
tiveram comportamento similar ao da
amiodarona isoladamente
7. ECG
Grupos
Resultado
s
Questões
Considerar
Lembra
r
Tratamento virgem de amiodarona: AMIODARONA =
ABLAÇÃO
Tratamento prévio com amiodarona: ABLAÇÃO> AUMENTO DA
DOSE
Efeitos Colaterais : AMIODARONA > ABLAÇÃO
Mexitil e Sotalol : Inferiores a AMIODARONA e
ABLAÇÃO
In patients with prior myocardial infarction
and recurrent episodes of VT or VF and
failed or are intolerant of amiodarone or
other antiarrhythmic medications catheter
ablation is recommended.
Dr. Henrique Maia
Coordenador da Residência de
Eletrofisiologia IHBDF
Co-Fundador do ArritmoCardio
Notas do Editor
"The clinical interpretation is that when patients experience ventricular arrhythmias despite antiarrhythmic drug therapy, catheter ablation should be considered and in some cases preferred, particularly among patients who have recurrent arrhythmias despite amiodarone," Sapp told heartwire . "Our next clinical question is, what should first-line therapy be?“
Dr John L Sapp
Sapp said, "I do think this is clinically significant, and that's bolstered by the fact not only are you achieving better arrhythmia outcomes after ablation, but you also have fewer treatment-attributable adverse events [22 vs 51; P=0.002]."
Patients who underwent ablation, however, stayed on their baseline dose of amiodarone to address new arrhythmias that may emerge, so ablation will not eliminate the need for amiodarone entirely, he added. "I hope that it will reduce the need for long-term and/or high-dose amiodarone for some patients.“
"we should not disregard this procedure because of no clear mortality benefit, because it seems to be very effective or at least more effective than antiarrhythmic drugs to use ablation to prevent shocks, which is a big problem for patients.“
In the 127 escalated-therapy and 132 ablation patients, appropriate ICD shocks occurred in 266 and 169 patients, respectively (P=0.28), and inappropriate shocks in 85 and 66, respectively (P=0.46).
Notably, there were two cardiac perforations, three cases of major bleeding, and three vascular injuries with ablation and two deaths from pulmonary toxicity and one from hepatic dysfunction with escalated therapy.
"the safety aspect was what really sold it to me. We all suspect that antiarrhythmic drugs have toxicity attached to them, but to have it pointed out so starkly as in this trial was very prominent. There were four deaths in the drug arm and none in the ablation arm—mind you, it's a sick population to be ablating in—but to have not a single death tells you how safe VT ablation has become.“
Dr Dhiraj Gupta
Deeper DiveIn
subgroup analyses, the rate of the primary outcome was significantly lower with ablation only among patients whose index arrhythmia occurred despite amiodarone at baseline (P=0.03 for interaction). Two-thirds of all patients were on amiodarone at baseline.